Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-01-04
2011-01-04
Robinson, Hope A (Department: 1652)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S350000, C530S300000, C514S002600, C514S013800
Reexamination Certificate
active
07863421
ABSTRACT:
Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4650858 (1987-03-01), Rasmussen et al.
patent: 4757006 (1988-07-01), Toole, Jr. et al.
patent: 4831119 (1989-05-01), Nordfang et al.
patent: 4868122 (1989-09-01), Kominek et al.
patent: 4970300 (1990-11-01), Fulton et al.
patent: 4994439 (1991-02-01), Longenecker et al.
patent: 5259951 (1993-11-01), Arrighi et al.
patent: 5298643 (1994-03-01), Greenwald
patent: 5397771 (1995-03-01), Bechgaard et al.
patent: 5565427 (1996-10-01), Freudenberg
patent: 5567422 (1996-10-01), Greenwald
patent: 5618788 (1997-04-01), Capon et al.
patent: 5618789 (1997-04-01), Capon et al.
patent: 5621039 (1997-04-01), Hallahan et al.
patent: 5637749 (1997-06-01), Greenwald
patent: 5739208 (1998-04-01), Harris
patent: 5766897 (1998-06-01), Braxton
patent: 5804420 (1998-09-01), Chan et al.
patent: 5932462 (1999-08-01), Harris et al.
patent: 5972885 (1999-10-01), Spira et al.
patent: 6037452 (2000-03-01), Minamino et al.
patent: 6048720 (2000-04-01), Dalborg et al.
patent: 7199223 (2007-04-01), Bossard et al.
patent: 2003/0077752 (2003-04-01), Cho et al.
patent: 2003/0118510 (2003-06-01), Patton et al.
patent: 2003/0161791 (2003-08-01), Bentley et al.
patent: 2003/0166536 (2003-09-01), Lollar
patent: 2004/0116649 (2004-06-01), Kozlowski
patent: 2005/0014903 (2005-01-01), Kozlowski et al.
patent: 2008/0058504 (2008-03-01), Bossard et al.
patent: 0 871 649 (2002-11-01), None
patent: 05-502161 (1993-04-01), None
patent: 59172425 (1998-11-01), None
patent: 11-513378 (1999-11-01), None
patent: WO 91/09122 (1991-06-01), None
patent: WO 92/16555 (1992-10-01), None
patent: WO 94/04193 (1994-03-01), None
patent: WO 94/15625 (1994-07-01), None
patent: WO 97/11957 (1997-04-01), None
patent: WO 98/51341 (1998-11-01), None
patent: WO 99/05333 (1999-04-01), None
patent: WO 00/78302 (2000-12-01), None
patent: WO 01/62827 (2001-08-01), None
patent: WO 02/09766 (2002-02-01), None
patent: WO 02/059179 (2002-08-01), None
patent: WO 2004/022629 (2004-03-01), None
patent: WO 2004/060406 (2004-07-01), None
patent: WO 2004/019499 (2004-10-01), None
patent: WO 2004/084948 (2004-10-01), None
patent: WO 2004/099231 (2004-11-01), None
patent: WO 2005/000360 (2005-01-01), None
PCT International Search Report, PCT Application No. PCT/US2004/006034 mail date Nov. 29, 2004.
Ouchi, et al., “Design of Antitumor Agent-Terminated Poly(Ethylene Glycol) Conjugate as Macromolecular Prodrug,” Polymer Preprints, vol. 38 ( No. 1), p. 582-583, 1997.
Sims, et al., “A Method for the Estimation of Polyethylene Glycol in Plasma Protein Fractions,” Analytical Biochemistry, vol. 107, p. 60-63, 1980.
Veronese, “Peptide and protein PEGylation: a review of problem and solutions,” Biomaterials, vol. 22, p. 405-417, 2001.
Zalipsky, “Chemistry of polyethylene glycol conjugates with biologically active molecules,” Adv. Drug Delivery Reviews, vol. 16, p. 157-182, 1995.
Zalipsky, et al., “Use of Functionalized Poly(Ethylene Glycol)s for Modification of Polypeptides in Polyethylene Glycol Chemistry: Biotechnical and Biomedical Applications,” Plenum Press, N.Y., p. 347-370, 1992.
Veronese, “Peptide and protein in PEGylation: a review of problem and solutions,” Biomaterials, vol. 22, p. 405-417, 2001.
Enzon Pharmaceuticals, “Macromolecular Engineering Technologies,” p. 1-14, 2004.
Nektar Transforming Therapeutics,, “Nektar Molecule Engineering: Polyethylene Glycol and Derivatives for Advanced PEGylation,” p. 1-20, Catalog 2003.
Nektar Transforming Therapeutics,, “Nektar Advanced PEGylation: Polyethylene Glycol and Derivatives for Advanced PEGylation,” p. 1-24, Catalog 2004.
NOF Corporation, “PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals ,” p. 1-46, Catalogue 2003-1st.
NOF Corporation, “PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals,” p. 1-50, Cataloge 2003-2nd.
NOF Corporation, “PEG Derivatives, Phospholipids and Drug Delivery Materials for Pharmaceutical Products and Formulations,” p. 1-59, Catalogue Ver. 8—Apr. 2006.
Polypure, “Products; PEG amines; PEG acids and amino acids; PEG thiols and disulfideds; ,” Biotins, Apr. 2004.
Polypure, “Products; PEG amines; PEG acids and amino acids; PEG thiols and disulfides,” Biotins, Apr. 2005.
Quanta Biodesign, “Labeling, Derivatization and Crosslinking Reagents for Biological and Related Materials with dPEG ,” p. 1-38, Mar. 12, 2004.
Quanta Biodesign, “Labeling, Modification and Crosslinking Reagents incorporating our unique monodispersed dPEG Technology,” p. 1-31, Nov. 5, 2004.
Quanta Biodesign Ltd., “Leading innovator, producer and provider of monodisperse discrete PEG (dPEG) derivatives,” p. 1-51, Updated: Jul. 18, 2005.
Quanta Biodesign Ltd., “Leading innovator, producer and provider of monodisperse discrete PEG (dPEG) derivatives,” p. 1-51, Nov. 17, 2005.
Shearwater Polymers, Inc., p. 2-49, Catalog—Mar. 1995.
Shearwater Polymers, Inc., “Polyethylene Glycol and Derivatives,” p. 1-53, Catalog Jun. 1997.
Shearwater Polymers, Inc., “Polyethylene Glycol and Derivatives: Functionalized Biocompatible Polymers for Research and Pharmaceuticals,” p. 1-50, Catalog 2000.
Shearwater Corporation, “Polyethylene Glycol and Derivatives for Biomedical Applications,” p. 1-17, Catalog 2001.
Lind, et al., “Novel forms of B-domain-deleted recombinant factor VIII molecules construction and biochemical characterization”, Eur. J. Biochem., vol. 232, pp. 19-27 (1995).
Rostin, et al., “B-domain deleted recombinant coagulation factor VII modified with monomethoxypolyethelyne glycol”, Bioconjugate Chem., vol. 11, pp. 387-396 (2000).
Bentley Michael D.
Bossard Mary J.
Zhang Ping
Evans Susan T.
King & Spalding LLP
Nektar Therapeutics
Robinson Hope A
LandOfFree
Polymer-factor VIII moiety conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polymer-factor VIII moiety conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymer-factor VIII moiety conjugates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2692230